128 related articles for article (PubMed ID: 25551558)
1. Epistasis as a determinant of the HIV-1 protease's robustness to mutation.
Capel E; Parera M; Martinez MA
PLoS One; 2014; 9(12):e116301. PubMed ID: 25551558
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.
Parera M; Fernàndez G; Clotet B; Martínez MA
Mol Biol Evol; 2007 Feb; 24(2):382-7. PubMed ID: 17090696
[TBL] [Abstract][Full Text] [Related]
3. Epistasis among deleterious mutations in the HIV-1 protease.
Parera M; Perez-Alvarez N; Clotet B; Martínez MA
J Mol Biol; 2009 Sep; 392(2):243-50. PubMed ID: 19607838
[TBL] [Abstract][Full Text] [Related]
4. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
[TBL] [Abstract][Full Text] [Related]
5. Strong Selection Significantly Increases Epistatic Interactions in the Long-Term Evolution of a Protein.
Gupta A; Adami C
PLoS Genet; 2016 Mar; 12(3):e1005960. PubMed ID: 27028897
[TBL] [Abstract][Full Text] [Related]
6. Strong epistatic interactions within a single protein.
Parera M; Martinez MA
Mol Biol Evol; 2014 Jun; 31(6):1546-53. PubMed ID: 24682281
[TBL] [Abstract][Full Text] [Related]
7. Evidence for positive epistasis in HIV-1.
Bonhoeffer S; Chappey C; Parkin NT; Whitcomb JM; Petropoulos CJ
Science; 2004 Nov; 306(5701):1547-50. PubMed ID: 15567861
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
Perryman AL; Lin JH; McCammon JA
Protein Sci; 2004 Apr; 13(4):1108-23. PubMed ID: 15044738
[TBL] [Abstract][Full Text] [Related]
9. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
10. Evolution. Epistasis in RNA viruses.
Michalakis Y; Roze D
Science; 2004 Nov; 306(5701):1492-3. PubMed ID: 15567846
[No Abstract] [Full Text] [Related]
11. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
12. Limits to detecting epistasis in the fitness landscape of HIV.
Biswas A; Haldane A; Levy RM
PLoS One; 2022; 17(1):e0262314. PubMed ID: 35041711
[TBL] [Abstract][Full Text] [Related]
13. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.
Menzo S; Monachetti A; Balotta C; Corvasce S; Rusconi S; Paolucci S; Baldanti F; Bagnarelli P; Clementi M
AIDS; 2003 Mar; 17(5):663-71. PubMed ID: 12646788
[TBL] [Abstract][Full Text] [Related]
14. A hierarchical model of HIV-1 protease drug resistance.
Goodsell DS
Appl Bioinformatics; 2002; 1(1):3-12. PubMed ID: 15130852
[TBL] [Abstract][Full Text] [Related]
15. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases.
Hong L; Treharne A; Hartsuck JA; Foundling S; Tang J
Biochemistry; 1996 Aug; 35(33):10627-33. PubMed ID: 8718851
[TBL] [Abstract][Full Text] [Related]
16. Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.
van Maarseveen NM; Wensing AM; de Jong D; Taconis M; Borleffs JC; Boucher CA; Nijhuis M
J Infect Dis; 2007 Feb; 195(3):399-409. PubMed ID: 17205479
[TBL] [Abstract][Full Text] [Related]
17. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
18. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
19. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
20. Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.
Braz AS; Tufanetto P; Perahia D; Scott LP
Proteins; 2012 Dec; 80(12):2680-91. PubMed ID: 22821809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
